Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regeneron’s Arcalyst available for prescription in US
Regeneron was granted marketing approval for Arcalyst by the FDA in February 2008, making it the only therapy approved for patients with cryopyrin-associated periodic syndromes (CAPS), a group
Regeneron was granted marketing approval for Arcalyst by the FDA in February 2008, making it the only therapy approved for patients with cryopyrin-associated periodic syndromes (CAPS), a group
Terms of the deal include upfront payments already made, future payments, R&D support as well as milestones for success for BioChemics (BCI). John Masiz, president & CEO of
In 69% of patients, the area treated with AN2728 scored better at the end of therapy than the area treated with the vehicle ointment, compared with six percent
The acquisition is a cash and stock transaction valued at $24 million, payable at closing, consisting of $7 million of cash and 2.2 million shares of Bio-Imaging stock
The multicenter, double-blind, placebo-controlled trial will evaluate the efficacy and safety of Adlea in reducing post-surgical pain in patients undergoing a bunionectomy procedure. The trial, to be conducted
The study is expected to be completed during the third quarter of 2008, with data available shortly thereafter. The results from this study will supplement the existing clinical
Orphan drug designation provides an important economic incentive for the development of new products in the cancer field. The US orphan drug designation provides for seven years of
Taro’s Ondansetron Injection is used for the prevention of nausea and vomiting associated with chemotherapy. This new Taro sterile injectable prescription product is bioequivalent to GlaxoSmithKline’s Zofran Injection,
An analysis of the data is expected in the second half of 2008. Based on prior discussions with the FDA the data could provide a registration path for
Under the terms of the agreement, Eczacibasi Ilac Pazarlama (EIP) will purchase the product from Pharming and market, sell and distribute it in Turkey. EIP will also pay